常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300255 常山药业

已收盘 04-30 15:00:00

{"stockData":{"symbol":"300255","market":"SZ","secType":"STK","nameCN":"常山药业","latestPrice":41.36,"timestamp":1777532634000,"preClose":41.22,"halted":0,"volume":18904426,"delay":0,"changeRate":0.0034,"floatShares":918000000,"shares":919000000,"eps":-0.3872,"marketStatus":"已收盘","change":0.14,"latestTime":"04-30 15:00:00","open":41.95,"high":43.8,"low":41.12,"amount":797000000,"amplitude":0.065,"askPrice":41.36,"askSize":126,"bidPrice":41.35,"bidSize":226,"shortable":0,"etf":0,"ttmEps":-0.3872,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":41.22,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":45.34,"lowLimit":37.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":919060878,"isCdr":false,"pbRate":31.31,"roa":"--","roe":"0.49%","epsLYR":-0.39,"committee":-0.245714,"marketValue":38012000000,"turnoverRate":0.0206,"status":0,"floatMarketCap":37953000000},"requestUrl":"/m/hq/s/300255/wiki","defaultTab":"wiki","newsList":[{"id":"2632767244","title":"每周股票复盘：常山药业（300255）2025年亏损3.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632767244","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632767244?lang=zh_cn&edition=full","pubTime":"2026-05-03 04:46","pubTimestamp":1777754771,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，常山药业报收于41.36元，较上周的39.59元上涨4.47%。本周，常山药业4月30日盘中最高价报43.8元。业绩披露要点：常山药业2025年归母净利润为-3.58亿元，同比下降43.46%。公司公告汇总：常山药业2025年年报显示，公司计划不派发现金红利，不送红股，不以公积金转增股本。股本股东变化股东户数变动截至2026年4月20日，常山药业股东户数为5.03万户，较4月10日减少2629户，减幅为4.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0172","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631578845","title":"常山药业（300255）2026年一季报简析：净利润同比增长55.21%，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631578845","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631578845?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:41","pubTimestamp":1777502489,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期常山药业发布2026年一季报。截至本报告期末，公司营业总收入2.56亿元，同比下降1.0%，归母净利润587.1万元，同比上升55.21%。本报告期常山药业短期债务压力上升，流动比率达0.74。本次财报公布的各项数据指标表现一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000022567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630158379","title":"常山药业（300255）披露2025年年度报告，4月28日股价下跌1.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630158379","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630158379?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:13","pubTimestamp":1777385617,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘，常山药业报收于39.15元，较前一交易日下跌1.63%，最新总市值为359.81亿元。该股当日开盘39.8元，最高40.22元，最低38.92元，成交额达5.45亿元，换手率为1.51%。近日，常山药业披露《2025年年度报告》。公告显示，截至2025年12月31日，公司总资产为4,351,189,589.78元，归属于上市公司股东的净资产为1,204,143,419.49元。2025年营业收入为875,132,346.58元，归属于上市公司股东的净利润为-357,895,551.22元，归属于上市公司股东的扣除非经常性损益的净利润为-356,952,357.57元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800064653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0172","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630308138","title":"图解常山药业一季报：第一季度单季净利润同比增长55.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630308138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630308138?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:39","pubTimestamp":1777372793,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业2026年一季报显示，一季度公司主营收入2.56亿元，同比下降1.0%；归母净利润587.1万元，同比上升55.21%；扣非净利润127.25万元，同比下降57.75%；负债率73.6%，财务费用2505.79万元，毛利率24.6%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629447814","title":"常山药业(300255)4月20日股东户数5.03万户，较上期减少4.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629447814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629447814?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:38","pubTimestamp":1777023522,"startTime":"0","endTime":"0","summary":"证券之星消息，近日常山药业披露，截至2026年4月20日公司股东户数为5.03万户，较4月10日减少2629.0户，减幅为4.96%。在化学制药行业个股中，常山药业股东户数高于行业平均水平，截至4月20日，化学制药行业平均股东户数为3.51万户。从股价来看，2026年4月10日至2026年4月20日，常山药业区间涨幅为4.55%，在此期间股东户数减少2629.0户，减幅为4.96%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0172","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629818510","title":"常山药业：公司暂时没有产品BD合作计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2629818510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629818510?lang=zh_cn&edition=full","pubTime":"2026-04-24 15:03","pubTimestamp":1777014185,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)04月24日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，请问贵公司产品有没有BD的计划？常山药业回复：你好，公司暂时没有产品BD合作计划。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400042220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0172","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629818306","title":"常山药业：公司出口产品以肝素原料药为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2629818306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629818306?lang=zh_cn&edition=full","pubTime":"2026-04-24 15:00","pubTimestamp":1777014023,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)04月24日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，请问贵公司肝素原料药及制剂出口情况如何？常山药业回复：你好。公司出口产品以肝素原料药为主，出口地区覆盖欧洲、东南亚、南美洲等地区。公司肝素制剂出口规模占公司收入比例较小，公司正积极推进肝素制剂海外注册工作，拓展产品出口范围。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400042161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629896277","title":"常山药业：艾本那肽目前尚未完成上市审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896277","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629896277?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:34","pubTimestamp":1777001656,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)04月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，贵司1类创新药阿贝那肽（艾本那肽）即将获批上市，上市后的营销推广和医保谈判是重中之重，请问贵公司是否已经做了相关部署？常山药业回复：你好。艾本那肽目前尚未完成上市审评，完成审评时间存在不确定性。由于艾本那肽完成审评时间存在不确定性，公司不方便介绍销售方面的具体准备情况。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400035034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300255","BK0172","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627404742","title":"常山药业最新公告：肝素钠注射液获吉尔吉斯斯坦药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2627404742","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627404742?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:26","pubTimestamp":1776241618,"startTime":"0","endTime":"0","summary":"常山药业(300255.SZ)公告称，公司近日收到通知，药品肝素钠注射液获得吉尔吉斯斯坦药品监督管理部门签发的药品注册证书。该药品主要用于防治血栓形成或栓塞性疾病等。本次获得注册批文对公司拓展海外市场带来一定积极影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500029160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0172","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627899418","title":"常山药业：药审中心网站公示了艾本那肽目前审评状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2627899418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627899418?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:04","pubTimestamp":1776150256,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，常山目前新药审评处于什么阶段？是完成综合审评后的最后审评阶段？还是仍处于专业审评，尚未开始综评的阶段？常山药业回复：你好。药审中心网站公示了艾本那肽目前审评状态，请予参考。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400018637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","300255","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627418360","title":"常山药业：那屈肝素钙注射液、依诺肝素钠注射液续标成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2627418360","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627418360?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:04","pubTimestamp":1776150256,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，请问贵公司1-8批国采续标情况如何？增量显著吗？常山药业回复：你好，公司那屈肝素钙注射液、依诺肝素钠注射液续标成功，公司正在积极推进后续销售工作。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400018642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0172","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627311433","title":"4月13日常山药业涨8.06%，医药LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627311433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627311433?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:17","pubTimestamp":1776068226,"startTime":"0","endTime":"0","summary":"证券之星消息，4月13日常山药业涨8.06%，收盘报44.37元，换手率5.27%，成交量48.33万手，成交额21.29亿元。重仓常山药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的医药LOF。医药LOF目前规模为6.54亿元，最新净值0.5615，较上一交易日上涨0.52%，近一年上涨6.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300020122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","BK1515","BK0239","BK0172","09939","BK0070","300255","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624953335","title":"4月1日常山药业涨5.72%，医药LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624953335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624953335?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:16","pubTimestamp":1775031400,"startTime":"0","endTime":"0","summary":"证券之星消息，4月1日常山药业涨5.72%，收盘报39.52元，换手率3.53%，成交量32.43万手，成交额12.71亿元。重仓常山药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的医药LOF。医药LOF目前规模为6.54亿元，最新净值0.5478，较上一交易日下跌0.27%，近一年上涨1.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100029120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK1574","BK0239","BK1161","300255","BK1515","BK0172","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820324","title":"常山药业（300255）发布为全资子公司提供担保的进展公告，3月27日股价上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820324","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622820324?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:06","pubTimestamp":1774620383,"startTime":"0","endTime":"0","summary":"近日，常山药业披露《关于为全资子公司提供担保的进展公告》。公告显示，公司于2026年3月26日与光大银行石家庄分行签订《最高额保证合同》，为全资子公司凯库得提供1,000万元的最高额连带责任保证担保；2026年3月27日，公司与农业银行正定县支行签订《保证合同》，为凯库得1,668.01万元的固定资产借款本金及利息提供连带责任保证。被担保人凯库得为公司全资子公司，非失信被执行人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700049218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0070","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621756877","title":"常山药业：通过药物研究院构建药物研发与信息共享中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2621756877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621756877?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:09","pubTimestamp":1774253351,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)03月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：1、公司有无市值管理理念或措施？2、公司科研团队建设情况？常山药业回复：你好，公司通过药物研究院构建药物研发与信息共享中心，通过新药最新前沿信息的分析、重点研发品种的选择、各类研发资源的整合以及研发人才的引进与培养等途径，发挥公司的创新主体作用。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300023982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0172","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621077565","title":"常山药业：公司在持续关注GLP-1药物研究最新前沿信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2621077565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621077565?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:09","pubTimestamp":1774253351,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业03月23日在投资者关系平台上答复投资者关心的问题。论坛重点讨论了GLP-1 长效周制剂，与公司核心产品阿贝那肽赛道高度契合，会议传递的心肾代谢获益、减重应用、基层推广等趋势，公司如何把握市场方向？常山药业回复：你好，公司在持续关注GLP-1药物研究最新前沿信息，实现充分利用既有技术成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300023986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0172","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775631","title":"常山药业：股东协议转让股份事项目前仍在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621775631?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:09","pubTimestamp":1774253349,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)03月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司领导你们好：股份转让是由公司发公告告知中小股东的，目前将近4个月还没结果，希望公司了解一下：目前股份转让是否正常？到了那个环节？谢谢！常山药业回复：你好。公司经向股东了解，股东协议转让股份事项目前仍在进行中。该事项由股东主导，公司不方便代替股东介绍交易细节。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300023978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300255","BK0172","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618499917","title":"常山药业：艾本那肽用于减重适应症的临床试验尚未完成准备工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2618499917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618499917?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:54","pubTimestamp":1773219256,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：减肥适应症临床几时开始，是否需要等待减重获批常山药业回复：你好。艾本那肽用于减重适应症的临床试验尚未完成准备工作，开展减重临床试验无需等待降糖适应症审批结果。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100027430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300255","BK0239","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618917298","title":"常山药业：截至2026年3月10日，公司的股东户数为47739户","url":"https://stock-news.laohu8.com/highlight/detail?id=2618917298","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618917298?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:54","pubTimestamp":1773219250,"startTime":"0","endTime":"0","summary":"证券之星消息，常山药业(300255)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止3月10日公司的股东人数是多少？谢谢!常山药业回复：你好。截至2026年3月10日，公司的股东户数为47739户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100027427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0172","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617727500","title":"常山药业(300255.SZ)：依诺肝素钠注射液获得塔吉克斯坦药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2617727500","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617727500?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:45","pubTimestamp":1772783150,"startTime":"0","endTime":"0","summary":"智通财经APP讯，常山药业(300255.SZ)发布公告，公司于近日收到通知，公司药品依诺肝素钠注射液获得塔吉克斯坦药品监督管理部门签发的药品注册证书。依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉内血栓形成)，特别是与骨科或普外手术有关的血栓形成;治疗已形成的深静脉栓塞，伴或不伴有肺栓塞，临床症状不严重，不包括需要外科手术或溶栓剂治疗的肺栓塞;与阿司匹林合用，治疗不稳定性心绞痛及非Q波心肌梗死;用于血液透析体外循环中，防止血栓形成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0172","300255","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777816785653,"stockEarnings":[{"period":"1week","weight":0.0314},{"period":"1month","weight":0.1065},{"period":"3month","weight":-0.2533},{"period":"6month","weight":-0.3761},{"period":"1year","weight":0.9667},{"period":"ytd","weight":-0.334}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"河北常山生化药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"50340人(较上一季度减少4.96%)","perCapita":"18228股","listingDate":"2011-08-19","address":"河北省石家庄市正定县中国(河北)自由贸易试验区正定片区高新技术产业开发区南区梦龙街71号","registeredCapital":"91906万元","survey":"　　河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是普通肝素原料药、低分子肝素原料药、低分子肝素制剂、普通肝素制剂。公司近几年分别被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等，建立了国家级博士后科研工作站，有效推动公司高级人才引进和创新驱动发展。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"常山药业,300255,常山药业股票,常山药业股票老虎,常山药业股票老虎国际,常山药业行情,常山药业股票行情,常山药业股价,常山药业股市,常山药业股票价格,常山药业股票交易,常山药业股票购买,常山药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}